Eli Lilly and Company $LLY Shares Sold by Arlington Financial Advisors LLC

Arlington Financial Advisors LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 21.8% during the second quarter, HoldingsChannel reports. The firm owned 508 shares of the company’s stock after selling 142 shares during the period. Arlington Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $396,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. WestEnd Advisors LLC grew its position in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, TD Capital Management LLC boosted its position in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. HSBC raised their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $948.06.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $812.65 on Wednesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $769.14 billion, a PE ratio of 53.11, a PEG ratio of 1.17 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company’s 50 day moving average price is $744.36 and its 200 day moving average price is $765.86.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm posted $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.